

## The approval of 『BRONUCK<sup>®</sup>』 (bromfenac sodium hydrate ophthalmic solution) as an import drug in China

On September 29, 2009, 『普罗纳克<sup>®</sup>』(BRONUCK<sup>®</sup>, bromfenac sodium hydrate ophthalmic solution) was approved as an import drug by the State Food and Drug administration (SFDA) in China.

普罗纳克 is a topical non-steroidal anti-inflammatory drug (NSAID) that is effective when used with twice-daily instillation. It has been used to treat the inflammatory disorder of the anterior segment and external eye as 『BRONUCK<sup>®</sup> 0.1% ophthalmic solution』 in Japan since July 2000. Moreover, it has been on the market as 『Xibrom<sup>™</sup> 0.9% ophthalmic solution』 in the United States since 2Q 2005, through licensee ISTA Pharmaceuticals, Inc. (Irvine, California).